LONDON (Reuters) – AstraZeneca is working with regulators to research a decrease dosage of its vaccine that carried out higher than a full dosage, a spokesman for the corporate mentioned, after its chief govt was quoted as saying an extra international trial was seemingly.
Requested in regards to the Bloomberg report on the extra trial, a spokesman for AstraZeneca mentioned: “As we communicated earlier this week, there may be robust benefit in persevering with to additional examine the half-dose/full dose routine.”
“We’re additional evaluating the info and can work with regulators on one of the best strategy for additional analysis. This may add to information from present trials that are at present being ready for regulatory submission,” he mentioned.
(Reporting by Alistair Smout, Enhancing by Rosalba O’Brien)
Copyright 2020 Thomson Reuters.